Information Provided By:
Fly News Breaks for March 27, 2017
EW
Mar 27, 2017 | 07:08 EDT
Evercore ISI analyst Vijay Kumar upgraded Edwards Lifesciences (EW) with an Outperform and a $110 price target. The analyst said investor expectations have moderated over the past 6 months and shares have underperformed Medtech peers, SURTAVI trial data supports a case for continued adoption of TAVR in IR patients, and believes there could be a decision in the Boston Scientific (BSX) litigation soon.
News For EW From the Last 2 Days
There are no results for your query EW